Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:
Leerink Partners 2025 Global Healthcare Conference
Location: Miami, FL
Presentation: Tuesday, March 11 at 8:00 a.m. ET
1x1 Meetings: Tuesday, March 11
To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at . A replay of the presentation will be available on the Ardelyx website for 30 days following the event.
Jefferies Biotech on the Beach Summit
Location: Miami, FL
1x1 Meetings: Wednesday, March 12
Barclays 27th Annual Global Healthcare Conference
Location: Miami, FL
Fireside Chat: Thursday, March 13 at 10:00 a.m. ET
1x1 Meetings: Thursday, March 13
To access the live webcast of the Barclays Fireside Chat, please visit the Events and Presentations page within the Ardelyx website at . A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit and connect with us on , and .
Investor and Media Contacts:
Caitlin Lowie
